Abstract:Racial and ethnic inequities in the receipt of medications to treat opioid use disorder (MOUD) have been well described. Ross and colleagues 1 provide an important addition to the existing literature on MOUD disparities, identifying racial differences in buprenorphine and methadone dosing across 3 trials completed within the National Institute on Drug Abuse Clinical Trials Network (CTN). Similar to prior research, Ross and colleagues 1 found a significant difference among methadone dosing among Non-Hispanic Black compared with Non-Hispanic White participants in their fully adjusted models. 2 Additionally, Ross and colleagues 1 describes differences in mean buprenorphine dosing and the proportion of participants receiving high buprenorphine or methadone doses among Non-Hispanic Black compared with Non-Hispanic White participants. Dosing disparities are particularly concerning because higher MOUD doses have been associated with greater retention in treatment. 3 While the differences identified were not significant after covariate adjustment (sex, age, withdrawal symptom severity, comorbid conditions, and drug use history), overadjustment and small sample sizes, particularly for the Non-Hispanic Black and Hispanic participants, may have limited the findings. The findings of Ross et al 1 must be understood in the context of the national randomized clinical trials whose data they analyzed. The first trial, the START trial (2006-2010), compared buprenorphine-naloxone and methadone in patients with opioid use disorder (OUD) with a primary outcome of liver function at 6 months (CTN-0027). Of note, a larger percentage of White participants who gave consent were screened out prior to randomization (75% vs 64%). 4 The second trial (2006-2009), the POATS study (CTN-0030 Phase 2), evaluated various doses of buprenorphine-naloxone with and without counseling for individuals with prescription opioid dependence, with a primary outcome of abstinence from nonprescribed opioids. Of note, this trial had the lowest rate of Non-Hispanic Black and Hispanic participants (7.5% compared with 27% in CTN-0027 and 30% in CTN-0051). Finally, the third trial, the X:BOT study (2014-2016), compared the effectiveness of intramuscular naltrexone vs buprenorphine-naloxone (CTN-0051). The first 2 trials took place prior to the introduction of fentanyl in the drug supply, with its emergence overlapping with CTN-0051. The Ross et al 1 secondary analysis pooled heterogeneous data on buprenorphine and methadone dosing and evaluated differences by race and ethnicity during the first 4 weeks of treatment. All studies included randomized treatment assignment and participants were from sites across the country. Each trial protocol provided similar dosing recommendations and allowed clinicians the flexibility to make adjustments based on clinical or subjective opioid withdrawal scores and clinical judgment. For a patient initiating methadone or burprenorphine to stabilize, a number of steps are necessary. First, they need to be assessed for, and diagnosed with, OUD. Then, they need access to a clinician who can prescribe MOUD or admission to an opioid treatment program, both of which require overcoming stigma, insurance, and transportation-related barriers. If the patient receives buprenorphine, certain insurance plans require prior authorizations for higher doses, mandate behavioral treatment attendance, or require frequent urine drug testing. 5 These barriers can be factors in stigma against addiction and may require additional clinical resources, which limits timely access to medications. For individuals receiving methadone, they typically must attend a specialized clinic daily and receive their medications under supervision. These clinics are only available in certain geographic areas and are often concentrated in high-poverty neighborhoods. Once a medication has been initiated, identifying stabilization with the right dose often requires frequent dose adjustments over several weeks. Finally, individuals must continue to take the medication as prescribed, attend follow-up visits, and meet treatment program requirements. Each step is subject to individual biases from clinicians, stigma against addiction, and structural racism in and outside of the health care setting–hindering progression along the OUD cascade of care. Policies within health care organizations, as well as state and national restrictive opioid-related policies, have had a negative impact in patient access to care and retention in care, especially for Black patients. While the clinical trial setting removes many barriers to medication access early in this pathway once enrolled, disparities in trial enrollment by race can affect the generalizability of the findings and limit confidence in the effectiveness of new treatments in clinical settings whe -Abstract Truncated-

Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails

Availability of Medications for Opioid Use Disorder in US Jails

Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails

Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration

Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative

Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment

"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose

"Yeah, this is not going to work for me"-The impact of federal policy restrictions on methadone continuation upon release from jail or prison

Jail Characteristics and Availability of Opioid Treatment Services: Results from a Nationally Representative Survey

Community-Based Medications First for Opioid Use Disorder - Care Utilization and Mortality Outcomes

Medications for Opioid Use Disorder in the Criminal/Legal System: Knowledge, Beliefs, and Attitudes Among Rural Community-Based Stakeholders

Emergency Department-Based Medication for Opioid Use Disorder Program: Addressing Gaps in Linkages to Care

Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review

Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts

Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review

Dosing Inequities in Opioid Use Disorder Treatment Trials

Addiction Consultation Services for Opioid Use Disorder Treatment Initiation and Engagement: A Randomized Clinical Trial

Attitudes and practices regarding the use of methadone in US state and federal prisons

Hospital Provider's Perspectives on MOUD Initiation and Continuation After Inpatient Discharge

The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections

Methadone Initiation in the Emergency Department for Opioid Use Disorder